On Drug Prices, Harris Pushes for Deeper Cuts While Trump Offers Few Specifics
Published On Oct 8, 2024, 1:07 PM
In the lead-up to the November election, Vice President Kamala Harris is promising to expand President Biden’s drug pricing policies, including limits on insulin costs and out-of-pocket expenses for older citizens. Meanwhile, former President Donald Trump has not laid out a clear plan on drug pricing, having recently changed his stance on price controls that would align U.S. drug prices with those in other countries. While drug pricing is not a central campaign issue, the outcome of the election could significantly impact policies affecting pharmaceutical costs and negotiations for Medicare.
Stock Forecasts
PFE
Negative
If Harris wins and expands drug pricing policies, companies producing drugs subject to these negotiations could see a reduction in revenues, potentially affecting their stock prices negatively. Conversely, a lack of major reforms under Trump could stabilize or even boost these stocks, considering his previous ties to the pharmaceutical lobby.
XBI
Positive
Companies focused on negotiating drug prices or providing cheaper medications could see a positive response in their stock as the public sentiment combines with potential legislative support from Harris's plan.
Related News
On Drug Prices, Harris Pushes for Deeper Cuts While Trump Offers Few Specifics
Oct 8, 2024, 1:07 PM
Both have campaigned for lower prescription costs. Kamala Harris has promised to expand President Biden’s policies. Donald Trump is a wild card.
Stock market today: Dow tumbles 400 points, tech rout leads Nasdaq, S&P 500 lower as 10-year yield tops 4%
Oct 7, 2024, 4:04 PM
Investors have overhauled their views on interest rate cuts after a blowout jobs report, ahead of a week of key inflation data and the start of earnings season.
Stock market today: Dow, S&P 500, Nasdaq slide as 10-year Treasury yield, oil jump
Oct 7, 2024, 2:58 PM
Investors have overhauled their views on interest rate cuts after a blowout jobs report, ahead of a week of key inflation data and the start of earnings season.